High risk of birth defects have prompted the FDA to develop a program to prevent unplanned pregnancies in women who are taking Accutane to control acne.
Pharmacists, physicians and patients will soon have to register with the "Ipledge" program in order to use or sell the drug to a customer. As part of the program, women will need to take pregnancy tests and agree to use two forms of birth control in order to receive Accutane or the generic.
The program will start in November. We'll have more information on this later in August when the FDA says it will make the program guidelines available to doctors and pharmacists.